Voices of Patients' Relatives to Support Weaning From Mechanical Ventilation
NCT ID: NCT03795623
Last Updated: 2023-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2019-02-01
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therefore, improving the weaning of stroke patients from mechanical ventilation is warranted to prevent ventilator-associated complications and eventually improve clinical outcomes.
This single-center, randomized, clinical trial aims at demonstrating that voices of patients' relatives support weaning from mechanical ventilation and reduce weaning failure in brain-injured patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Can a Vocal Stimulus Provoke Spontaneous Breathing in an Ischemic Stroke Patient Dependent on Mechanical Ventilation?
NCT02114996
Weaning From Mechanical Ventilation in Patients With Acute Brain Injury
NCT06542107
Predictors of Weaning Outcomes for Brain Injured Patients
NCT02863237
Early Speaking Valve in Ventilator Weaning: Effects on Communication, Depression, and Quality of Life
NCT07005596
Mechanical Ventilation in Brain-injured Patients
NCT01885507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When conversion from controlled to assisted mechanical ventilation is intended according to standard treatment, audio recordings will be administered in repeat mode for 10 minutes and performed three times per day. If spontaneous breathing trials (SBT) are intended according to standard treatment, the audio recordings will be played during the SBT three times per day.
Criteria for weaning not to be intended - according to Boles et al. (Weaning from mechanical ventilation. Eur Respir J. 2007) and adapted to neurological patients:
Objective measurements:
* Unstable clinical condition
* Cardiovascular status (fC≥140/min, systolic BP \<90mmHg or \>180mmHg, more than minimal vasopressors)
* Metabolic status (e.g. inacceptable electrolytes)
* Inadequate oxygenation
* SaO2 ≤90% on FiO2 \>40% or pO2/FiO2 \<150mmHg or pO2/FiO2 \<120mmHg in case of chronic hypoxemia (Horowitz index)
* PEEP\>8cmH2O
* Inadequate pulmonary function
* fR ≥35/min
* MIP\>(-20 -) -25cmH2O
* VT ≤5ml/kgKG
* VC ≤10ml/kgKG
* fR/VT ≥105 breaths/min x l (RSBI)
* significant respiratory acidosis (pH≤7.25)
* Unstable neurological condition
* sedation or inadequate mentation on sedation
* present or anticipated intracranial mass effect (e.g. midline shift \>10mm or progression, basal cistern effacement or oculomotor disturbance, signs of transfalxial/transtentorial/transforaminal herniation
* elevation of intracranial pressure (\>20 cmH2O) and/or obstructive hydrocephalus
* severe vasospasms (\>6 kHz in transcranial Doppler, or determined by CT-A/CT-P)
* status epilepticus (determined by EEG)
* acute intracranial infection (without established and/or treated origin)
Clinical assessment:
* Inadequate cough
* Excessive tracheobronchial secretion
* Disease acute phase for which the patient was intubated
Ethics Approval: The Institutional Review Board of the Friedrich-Alexander-Universität Erlangen-Nürnberg approved of the study on 13 November 2018.
Sample Size Calculation: The sample size is computed with 80% power and a 5% α-risk for the hypothesis of Voice Weaning achieving a 15% absolute weaning failure reduction. The sample size is increased by 10% to correct for dropouts and lost to follow up: a maximum of 354 patients will be included and an interim analysis be performed after inclusion of 50% of the calculated subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional arm
Muted audio recordings of the patients relatives.
Sham control
Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Voice-Weaning arm
Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
Voice-Weaning
Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Voice-Weaning
Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Sham control
Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weaning from mechanical ventilation intended by the attending physician
* Obtained informed consent from the legal representative
Exclusion Criteria
* History of psychiatric disease
* Weaning from mechanical ventilation not intended or decision to limit therapeutic interventions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hagen B. Huttner
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hagen B. Huttner, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Erlangen-Nürnberg Medical School, Department of Neurology, Germany
Joji B. Kuramatsu, MD
Role: PRINCIPAL_INVESTIGATOR
University of Erlangen-Nürnberg Medical School, Department of Neurology, Germany
Maximilian I. Sprügel, MD
Role: PRINCIPAL_INVESTIGATOR
University of Erlangen-Nürnberg Medical School, Department of Neurology, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Giessen
Giessen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
417_18 B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.